The Effect of Fibrinolysis Inhibitors on the Ellagic Acid Activation of Hageman Factor in the Dog

Summary

The administration of 10 ml/kg b.w. of a 10⁻⁴ M ellagic acid solution to dogs primed with saline (control group) caused a marked shortening of the silicone clotting time and a mild shortening of the glass clotting time whereas no changes in the euglobulin lysis time were noted. The administration of the compound to dogs primed with Trasylol (10,000 K.I.U./kg b.w.) failed to cause any change in the clotting times but caused instead a sharp inhibition of fibrinolysis. The administration of ellagic acid to dogs primed with EACA (0.3 g/kg b.w.) caused a shortening of the silicone and glass clotting times similar to that observed in the control group whereas fibrinolysis was not significantly inhibited. These data indicate that Trasylol inhibits Hageman factor activation by ellagic acid whereas EACA has no effect.

^* From the Institute of “Clinica Chirurgica”, University of Padua Medical School.

• References

• 1 Amris C. J, Hilden M. Inhibition of thromboplastin activity by Trasylol. In vitro investigation concerning the mechanism of inhibition. Scand. J. Haemat 04: 3 1967;
• 2 Amris G. J. Inhibition of fibrinolytic and thromboplastic activity by Trasylol. Scand. J. Haemat 03: 19 1966;
• 3 Back N. Pharmacology of a tissue proteinase inhibitor. In: Proceedings Symposium on Proteinase inhibitors in Medicine and Surgery. London: Oct. 1967: 2.
• 4 Back N. Some studies on the use of proteinase inhibitors in experimental shock states. In: Proceedings Symposium on proteinase inhibitors in Medicine and Surgery. London: Oct. 1967: 83.
• 5 Blombäck B, Blombäck M, Olsson P. Action of a proteolytic enzyme inhibitor on blood coagulation in vitro. Thrombos. Diathes. haemorrh. (Stuttg) 18: 190 1 1967;
• 6 Botti E, Ratnoff O. D. Studies on the pathogenesis of thrombosis: an experimental “hyper - coagulable state” induced by intravenous injection of ellagic acid. J. Lab. clin. Med 64: 385 1064;
• 7 Botti E. Assessement of the hypercoagulable state and ellagic acid. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl 20: 49 1966;
• 8 Cliffton E. E, Cannamella D. A. Fibrinolytic and proteolytic activity of human plasminogen prepared from fraction III of human plasma. J. appl. Physiol 06: 42 1953;
• 9 Dubber A. H. C, MC Nicol G. P, Douglas A. S. In vitro and in vivo studies with Trasylol, an anticoagulant and a fibrinolytic inhibitor. Brit. J. Haemat 14: 31 1968;
• 10 Gautvik K. M, Rugstad H. E. Kinin formation and kininogen depletion in rats after intravenous injection of ellagic acid. Brit. J. Pharm. Chemoth 31: 390 1966;
• 11 Gallioli G, Cappelli F, Esposito R, Lotto A, Bernardi R. Impiego sperimentale dell’acido ellagico come procoagulante. Atti Ac. Med. Lomb 21: 1 1966;
• 12 Girolami A, Agostino D, Cliffton E. E. The effect of ellagic acid in the coagulation in vivo. Blood 27: 93 1966;
• 13 Girolami A. Azione dell’acido ellagico purificato sul tempo di coagulazione. Raffronto con l’acido ellagico grezzo. Haemat 51: 96 1966;
• 14 Girolami A, Cliffton E. E. Hypercoagulable state induced in humans by the intravenous administration of purified ellagic acid. Thrombos. Diathes. haemorrh. (Stuttg) 17: 165 1967;
• 15 Girolami A. The action of ellagic acid on the coagulation mechanism and experimental and clinical bleeding. Haemat. Lat 10: 291 1967;
• 16 Girolami A, Scarpa R. Ellagic acid induced thromboelastographic changes in the normal individual and in several coagulopathies. Haemat. Lat 12: 143 1969;
• 17 Girolami A. Further studies on the ellagic acid induced hypercoagulable state. Lack of thrombosis in the dog after long term administration of the compound. Coagulation 02: 263 1969;
• 18 Girolami A. Acido ellagico ed emostasi. Rec. Progr. Med 47: 365 1969;
• 19 Girolami A, Zacchello G, D’Elia R. Congenital afibrinogenemia. A case report with some considerations on the hereditary transmission of disorder. Thrombos. Diathes. haemorrh. (Stuttg) 25: 460 1971;
• 20 Girolami A, Lazzarin M, Scarpa R, Brunetti A. Unpublished observations.
• 21 Glueck H. I, Roehll W. Myocardial infarction in a patient with a Hageman (factor XII) defect. Ann. intern. Med 64: 390 1966;
• 22 Hoak J. C, Swanson L. W, Warner E. D, Connor W. E. Myocardial infarction associated with severe factor XII deficiency. Lancet II: 884 1960;
• 23 latridis S. G, Ferguson J. H. Active Hageman factor. A plasma lysokinase of the human fibrinolytic system. J. clin. Invest 41: 1277 1962;
• 24 latridis S. G, latridis P. G, Ferguson J. H. Effect of ellagic acid upon the human fibrinolytic system. Thrombos. Diathes. haemorrh. (Stuttg) 16: 436 1966;
• 25 MC Kay D. G, Muller-Bergbaus G, Cruse V. Activation of Hageman factor by ellagic acid and the generalised Shwartzman reaction. Amer. J. Path 54: 394 1969;
• 26 Niewiarowski S. O, Prou-Wartelle O. Rôle du facteur contact (facteur Hageman) dans la fibrinolyse. Thrombos. Diathes. haemorrh. (Stuttg) 03: 593 1959;
• 27 Nordstram S. Inhibition of blood coagulation by Trasylol. In vitro and in vivo studies on dog blood. Coagulation 03: 159 1970;
• 28 Prentice C. R. M, MC Nicol G. P, Douglas A. S. Studies on the anticoagulant action of Aprotinin (Trasylol). Thrombos. Diathes. haemorrh. (Stuttg) 24: 265 1970;
• 29 Ratnoff O. D, Crum J. D. Activation of Hageman factor by solution of ellagic acid. J. Lab. clin. Med 62: 359 1964;
• 30 Ratnoff O. D, Busse R. J, Sheon R. P. The demise of John Hageman. New Engl. J. Med 279: 760 1968;
• 31 Trautschold I, Werle E, Zickgraf-Rüdel G. Trasylol. Biochem. Pharm 16: 59 1967;